newsfilter
← Interviews
All-In Podcast31 min

Inside the GLP-1 Gold Rush: Eli Lilly CEO on New Breakthroughs, Addiction & Mental Health, Pricing

Dave Ricks, Chamath, Jason, Friedberg

Fireside Chat, Interview

Eli Lilly CEO David Ricks has steered the company to an 860% market capitalization increase and record-breaking Mounjaro sales by leveraging a massive research workforce and aggressive manufacturing expansion to secure global dominance in GLP-1 therapies. While the firm faces capital shortages in the broader biotech sector, it is diversifying its pipeline beyond weight loss to address brain disorders and developing oral formulations to improve accessibility without compromising the high R&D reinvestment model Ricks defends. Personalized by Ricks' own successful treatment, the company balances aggressive clinical innovation with strategic supply chain controls to maintain its competitive edge against emerging international rivals.